Dental Care Clinics in Capitola, CA Accepting Medicare
4 Dental Care Clinics found. Showing 1 - 4
 Lindy B Bixby Dds, Incorporated Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 824 Bay Ave, Suite 30, Capitola, CA 95010 Phone: 831-464-4222 Fax: 831-464-4225 |
North Coast Orthodontics Dentist - Orthodontics and Dentofacial Orthopedics Medicare: Not Enrolled in Medicare Practice Location: 1830 41st Ave., Capitola, CA 95010 Phone: 831-426-4344 Fax: 831-426-5223 |
Capitola Kids Dentistry Clinic/Center - Dental Medicare: Not Enrolled in Medicare Practice Location: 2001 40th Ave, Suite G, Capitola, CA 95010 Phone: 831-464-5555 Fax: 831-464-5558 |
Ronconi Salinas Valley Dental Practice Clinic/Center - Dental Medicare: Not Enrolled in Medicare Practice Location: 824 Bay Ave Ste 30, Capitola, CA 95010 Phone: 831-464-4222 Fax: 831-464-4225 |
News Archive
New non-invasive method to diagnose osteoarthritis
Researchers at New York University have developed an innovative way to look at the development of osteoarthritis in the knee joint-one that relies on the examination of sodium ions in cartilage. Their work, which appears in the Journal of Magnetic Resonance, may provide a non-invasive method to diagnose osteoarthritis in its very early stages.
Long-term ozone exposure linked to adverse health effects
A new study has utilized a novel method to estimate long-term ozone exposure and previously reported epidemiological results to quantify the health burden from long-term ozone exposure in three major regions of the world.
FDA clears Stryker's Trevo Pro Retriever to treat acute ischemic stroke
Stryker Neurovascular announced today that its Trevo Pro Retriever has been granted 510(k) market clearance by the U.S. Food and Drug Administration. The Trevo Pro Retriever is the next generation in clot removal technology from Stryker, utilizing proprietary Stentriever Technology for optimized clot integration and retrieval in patients experiencing acute ischemic stroke.
Shire Canada receives expanded indication for MEZAVANT for treatment of ulcerative colitis
Shire Canada Inc., a division of Shire plc, the global specialty biopharmaceutical company, is proud to announce that MEZAVANT® (mesalamine delayed and extended release tablets), the first and only once-daily mesalamine indicated for the induction of clinical and endoscopic remission in patients with mild-to-moderate, active ulcerative colitis (UC), has received an expanded indication to include maintenance of clinical and endoscopic remission (mucosal healing) in patients with ulcerative colitis.
› Verified 2 days ago